secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2023-07-17T23:59:59+00:00
Accession:  0000950170-23-033196
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar Therapeutics appoints Russell Clayton as CMO, 180K stock option inducement grant
--------------------------------------------------------------------------------

- Russell 'Rusty' Clayton appointed Chief Medical Officer effective July 17, 2023, succeeding Nancy M. Ruiz (retiring).
- Dr. Clayton previously served as Principal at Aeremedea, LLC and as advisor to Larimar for 5 years.
- Inducement award of 180,000 stock options granted under Nasdaq Listing Rule 5635(c)(4), vesting over 4 years.
- Dr. Clayton brings ~20 years of rare disease experience, including roles at Alcresta Therapeutics and Merck.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017023033196/0000950170-23-033196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017023033196/lrmr-20230717.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-033196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer